Cycle Pharmaceuticals (Cycle Group) Acquires Applied Therapeutics, Inc.

Cyclo Therapeutics Merges with Applied Molecular Transport; Combined Company to Operate as Cyclo Therapeutics, Inc.

December 27, 2023

Biotechnology

Cyclo Therapeutics completed an all-stock merger with Applied Molecular Transport (AMT), with AMT shareholders receiving 0.1331 shares of Cyclo Therapeutics for each AMT share (approximately 5,822,720 Cyclo shares, or ~18% of the combined company). The combined, Nasdaq-listed company will operate as Cyclo Therapeutics, focus on advancing the Phase 3 TransportNPC study of Trappsol Cyclo for Niemann-Pick Disease Type C1, be led by Cyclo's existing management and headquartered in Gainesville, Florida.

BiomX Acquires Adaptive Phage Therapeutics

March 18, 2024

Biotechnology

BiomX Inc. completed a stock-for-stock acquisition of Adaptive Phage Therapeutics (APT), making APT a wholly owned subsidiary and combining phage therapy capabilities and pipelines. Concurrently, BiomX raised $50 million in a private placement led by affiliates of Deerfield Management and the AMR Action Fund to advance two Phase 2 assets (BX004 and BX211) toward pivotal readouts in 2025–2026.

Sorrento Therapeutics Acquires ACEA Therapeutics

June 1, 2021

Biotechnology

Sorrento Therapeutics completed the acquisition of ACEA Therapeutics, making ACEA a wholly owned subsidiary and issuing Sorrento common stock plus contingent milestone and royalty payments. The deal adds multiple clinical- and preclinical-stage new chemical entities (including abivertinib) to Sorrento's oncology and immunotherapy pipeline and expands its development and manufacturing footprint in China and North America.

Norgine Acquires Theravia

August 14, 2025

Pharmaceuticals

Norgine has completed the acquisition of Theravia, an international pharmaceutical company focused on therapies for rare and debilitating conditions. Theravia is now a wholly owned subsidiary of Norgine as the buyer begins integration to expand its rare-disease portfolio and extend product reach across Europe and Australia/New Zealand.

Century Therapeutics Acquires Clade Therapeutics; Raises $60M Private Placement Led by Bain Capital Life Sciences

April 11, 2024

Biotechnology

Century Therapeutics agreed to acquire privately held Clade Therapeutics for approximately $35 million in upfront consideration (plus a potential $10 million milestone) to expand its iPSC-derived cell therapy pipeline and next-generation Allo-EvasionTM platform. Concurrently, Century completed a roughly $60 million private placement led by Bain Capital Life Sciences and several institutional investors to support expanded autoimmune development of its lead program CNTY-101 and extend cash runway into 2026.

Catalyst Clinical Research Acquires Aptus Clinical

May 4, 2022

Healthcare Services

Catalyst Clinical Research, a portfolio company of NovaQuest Capital Management, has acquired U.K.-based Aptus Clinical to accelerate Catalyst's European expansion and broaden its oncology and early-phase clinical services. The deal creates a multi-region CRO operating across North America and Europe, increases Catalyst's patient reach by nearly 600 and lifts combined headcount to more than 800.